Scorpius announced the launch of Scorpius Ventures, a new business unit designed to support emerging biotech companies with a flexible American onshoring model. By combining service fees with an equity stake, Scorpius Ventures lowers financial barriers for its partners to onshore production of their biologics, creating a mutually beneficial pathway to accelerate biotech advancements. “At Scorpius, we’re committed to enabling biotech innovation by aiming to reduce financial obstacles and creating true partnerships,” said Jeff Wolf, CEO of Scorpius Holdings (SCPX). “Through Scorpius Ventures, we’re providing biotech companies the resources they need to advance critical therapies through a hybrid fee and equity model, thereby, fostering shared success while advancing our mission to strengthen U.S. biosecurity and manufacturing independence.”
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SCPX:
- Eleven option delistings on November 18th
- Scorpius Holdings announces collaboration with Celltheon Corp
- Scorpius Holdings announces implementation of new cost saving measures
- Scorpius Holdings announces partnership with U.S. biotech company
- Scorpius Holdings selected to join Medical CBRN Defense Consortium
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
